Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01183910
NCT01183910
Unknown
N/A

A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Safety and Efficacy of a Novel Oral Natural Extract for the Treatment of Senile Purpura

Nexgen Dermatologics, Inc.1 site in 1 country75 target enrollmentNovember 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPURPURA

Overview

Phase
N/A
Intervention
Not specified
Conditions
PURPURA
Sponsor
Nexgen Dermatologics, Inc.
Enrollment
75
Locations
1
Primary Endpoint
IMPROVEMENT IN PATIENT'S SKIN APPEARANCE WITH SENILE PURPURA
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

A randomized, double-blind, placebo controlled study to assess the safety and effectiveness of a novel oral natural extract to improve the appearance of the skin of patients with senile purpura.

Registry
clinicaltrials.gov
Start Date
November 2008
End Date
August 2011
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients with evidence of purpura on physical exam

Exclusion Criteria

  • •Preexisting condition that would not allow the patients to take oral calcium supplement

Outcomes

Primary Outcomes

IMPROVEMENT IN PATIENT'S SKIN APPEARANCE WITH SENILE PURPURA

Time Frame: 6 WEEKS

Secondary Outcomes

  • ADVERSE EFFECTS IN PATIENTS WITH SENILE PURPURA TAKING THIS MEDICATION(6 WEEKS)

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Phase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisPulmonary FibrosisPulmonary Fibrosis Secondary to Systemic SclerosisPulmonary Fibrosis, Interstitial Lung DiseaseInterstitial Lung DiseaseInterstitial Lung Disease Due to Connective Tissue Disease (Disorder)Interstitial Lung Disease in Patients With Rheumatoid ArthritisInterstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified ElsewhereHypersensitivity PneumonitisInterstitial Lung Disease With Systemic Sclerosis
NCT06329401Avalyn Pharma Inc.375
Completed
N/A
A Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver HealthNon-Alcoholic Fatty Liver Disease
NCT05808049Vedic Lifesciences Pvt. Ltd.60
Completed
Phase 3
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's DiseaseCrohn's Disease
NCT01277666GlaxoSmithKline608
Active, Not Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA VaccineCOVID-19
NCT05636319Suzhou Abogen Biosciences Co., Ltd.14,168
Completed
Phase 2
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract InfectionsComplicated Urinary Tract InfectionAcute Pyelonephritis
NCT03445195Entasis Therapeutics80